Multiple sclerosis drug pipeline
Since a theoretical model of the disease is hypothesized, until a drug appears that interferes with one of its pathways, several phases must be completed. First an animal model of the pathway to be studied must be developed, and the possible drugs that will be tried to interfere with it must be tried out. After that, three phases of human testing begin, and if everything works as expected, finally the drug will reach the status of approved by the regulatory agencies.
Approved medication
As of 2016, there are 10 active principles approved for RRMS and one for SPMS. Currently there is nothing approved for PPMS.
The approved drugs for RRMS are: Two interferons (interferon beta-1a and interferon beta-1b), glatiramer acetate, mitoxantrone, teriflunomide,[1] dimethyl fumarate,[2] one S1P modulator (fingolimod) and finally three monoclonal antibodies (natalizumab, alemtuzumab[3] and since May 2016 daclizumab[4][5]).
Only one of them, Mitoxantrone, has been approved for Secondary Progressive MS (SPMS) and for the special course of PPMS "rapidly progressive multiple sclerosis".[6] There is no disease-modifying treatment for normal Primary Progressive (PPMS), but currently several new drugs are being tried out in clinical trials.
Cleared for review and fast track
When a company considers that there is enough information from clinical trial to fill an application, they submit to the regulatory agencies a request for approval. When the agency considers that the request is worthy to be evaluated they grant the state "under review" to the drug. Some regulatory agencies have special workflows for drugs that cover something uncovered, like the FDA fast track.
- Cladribine (under development by Merck Serono; anticipated brand name: Movectro) is an antineoplastic oral drug with immunosuppressive effects. It is already currently used as an intravenous infusion to treat hairy cell leukemia (leukemic reticuloendotheliosis). An oral version of cladribine is in phase III.[7] The completion of the phase III program took place in early 2009 meeting its main endpoint with 58% relative reduction in annualized relapse rates with respect to placebo.[8] Formal submission to European EMEA took place in middle 2009. In January 2010, researchers published in NEJM significant results of cladribine use in reducing relapsing course of multiple sclerosis.[9] This drug was expected to be in the market in 2011 for use in multiple sclerosis patients.,[10][11] but in 2011 the company decided to stop selling the tablets in Russia and Australia though it was already approved in this countries.[12] Nevertheless, it seems that approval process continued in Europe and the EMEA has accepted a review process[13]
- Ocrelizumab (proposed trade name Ocrevus), Anti-CD20 humanized monoclonal antibody, whose mechanism of action targets B-Cells, like Rituximab, currently having passed a phase III trial.[14] As of 2016 the drug has completed already a phase III trial showing NEDA (No Evidence of Disease Activity) status achievement.[15] Cleared for review in FDA and EMEA since 30/6/16 for relapsing and primary progressive MS.[16]
- Ibudilast: A phase II trial shows that Ibudilast does not reduce lesion rate, but prevents them to turn into black holes. They classify its action as class III evidence of delay on disease activity[17] In March 2016 Ibudilast was designated a FDA fast track candidate for progressive MS[18]
Phase III
Phase III programs consist of studies on large patient groups (300 to 3,000 or more) and are aimed at being the definitive assessment of how effective and safe a test drug will be. It is the last stage of drug development and is followed by a submission to the appropriate regulatory agencies (e.g., European Medicines Agency (EMEA) for the European Union, the Food and Drug Administration (FDA) for the United States, Therapeutic Goods Administration (TGA) for Australia, etc.) to obtain approval for marketing. Treatment in MS phase III studies is usually 2 years per patient.
- Angioplasty for chronic cerebrospinal venous insufficiency (the so-called Zamboni liberation procedure), currently in phase III.[19] The treatment uses an inflatable balloon (instead of stenting) to open narrowed blood vessels in hopes of improving blood flow, based on the hypothesis that a compromised blood drainage system can debilitate the blood–brain barrier.[20]
- Tovaxin (injectable) A vaccine against self T-Cells, which consist of attenuated autoreactive T cells. It is developed by Opexa Therapeutics, (previously known as PharmaFrontiers), and finished a phase IIb September 2008,[21] failing its primary target though in March 2008 was still performing good.[22] After several financial troubles, a phase III trial has been granted in 2011[23]
- Siponimod, (BAF312) is a sphingosine-1-phosphate receptor modulator for oral use for MS. A phase III trial should run from Dec 2012 to Dec 2016.[24]
- Masitinib, anticancer drug that blocks cell replication and immune responses[25]
- MD1003 based on a highly concentrated dosis Biotin has also passed a phase III trial for progressive MS[26]
Phase II
Phase II studies are performed on mid-sized groups of patients (20 to 300) and are designed to assess whether a drug may work in the targeted disease area, as well as to continue earlier safety assessments obtained in healthy volunteers. Treatment in MS phase II studies is with 4–12 months usually shorter than in phase III studies.
- ATL1102 (under development by Teva and Antisense therapeutics) is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Results of a Phase IIa have been reported.
- CDP323 (under development by UCB S.A. and Biogen) is a compound for oral intake acting against α4-integrin, i.e., it has the same mechanism of action as natalizumab. Phase II investigations started in 2007.[27]
- Estradiol and estrogen receptors(ER): Both have been shown to be antiinflammatory and neuroprotective in a variety of neurological disease models and now is known that they work also in presence of inflammation[28][29]
- Inosine: Inosine is a compound that has shown interesting preliminary results in phases I and II clinical trials.[30][31] Two different mechanisms of action have been proposed. First, it produces uric acid after ingestion,[32] which is a natural antioxidant;[33] second, it has been shown to induce axonal rewiring in laboratory animals with stroke,[34] and spinal cord injury.[35] However it can cause health problems in a long-term treatment,[36] mainly kidney stones.[37] It seems that its mechanism of action is peroxynitrite inactivation[38] Other reports point to an immune modulation[39]
- Ofatumumab, other anti-CD20 monoclonal antibody, also in phase II for MS, and phase III for others autoimmune diseases
- Stem cell transplantation was found feasible in a phase I/II study in 21 patients with relapsing-remitting MS not responsive to interferon beta. It involves collecting some of the patient's own peripheral blood stem cells, giving low-intensity chemotherapy to eliminate auto-reactive lymphocytes, and then reinfusing the stem cells.[40] Earlier studies in the secondary-progressive stage of MS have failed to shown reversal of neurological symptoms.
- Amiselimod, S1P modulator[41]
Phase I and animal models
Phase I and medicaments used in animal models would make a huge list. Here only some of them with special interest are listed.
- GIFT15 is a treatment which suppresses the immune system, and has been successfully used in the treatment of mice. The immune system attacks the central nervous system in Multiple Sclerosis patients. Specifically a "granulocyte-macrophage colony–stimulating factor (GM-CSF) and interleukin-15 (IL-15) 'fusokine]' (GIFT15) exerts immune suppression via aberrant signaling through the IL-15 receptor on lymphomyeloid cells. We show here that ex vivo GIFT15 treatment of mouse splenocytes generates suppressive regulatory cells of B cell ontogeny (hereafter called GIFT15 Breg cells)."[42][43][44]
- Bosentan, endothelin-1 antagonist, has been proposed to lower the ET1 levels, which are involved in brain hypoperfusion[45]
Research into progressive variants
Progressive variants are more difficult to treat than the Relapsing-Remitting course. Normally research for PPMS and SPMS goes together, being more difficult to treat PPMS. Therefore, we present here the research on SPMS with a mention to PPMS when applicable
Relapsing-Onset variants (RO), even when they turn into progressive, have proved easier to treat than Progressive-Onset variants. Though difficult to treat, Secondary progressive and progressive-relapsing are easier to treat than PPMS. Only Mitoxantrone has been approved for them, but most of the previous pipeline drugs have been or will be tried on it at some point. At this moment several therapies are under research:
- Cyclophosphamide (trade name Revimmune) is currently in Phase III for secondary progressive MS.[46] It was also studied for RRMS but the company does not pursue actively this path. After a 2006 study for refractory cases it showed good behaviour[47] Later, a 2007 open label study found it equivalent to Mitoxantrone[48] and in 2008 evidence appeared that it can reverse disability.[49]
- Simvastatin, a cholesterol-lowering statin, Simvastatin (Zocor), has shown good results in progressive variants[50] This has shown brain atrophy reduction in secondary progressive MS.[51] This drug is under research for PPMS and SPMS.
- Tcelna is currently under active research by Opexa, showing promising results.[52]
Some PPMS patients with a special biomarker (Immunoglobulin M oligoclonal bands) have been shown to respond to standard RRMS medications, though there is only preliminary evidence waiting to be confirmed[53]
Other possible treatments under research
- Antimicrobial agents against Chlamydophila pneumoniae: MS patients are more likely to have detectable levels of Chlamydophila pneumoniae DNA in their cerebrospinal fluid, compared to other patients with neurological diseases; however these findings are insufficient to establish an etiologic relation.[54] Anecdotal reports of the use of antimicrobial agents against Chlamydophila pneumoniae are favorable, but only one double-blind placebo-controlled trial has been published, in which the number of patients studied was too small (four in each arm of the trial) to reach statistical significance in the primary outcome measure (volume of gadolinium-enhancing lesions, as viewed on MRI).[55]
- Antioxidants, available as supplements, are reported to reduce the blood–brain barrier permeability.[56] Related to this, MS patients have been reported to have low levels of uric acid, which is a natural antioxidant,[57] and has been observed that raising uric acid levels protects against blood–brain barrier destruction (through peroxynitrite scavenging ).[58] Peroxynitrite has been correlated with the axons degeneration and its removal can protect neurons from further damage after an attack. They can also remove other reactive oxygen species[59] It is also known that uric acid levels decrease during the course of the disease[60]
- Bilirubin has been found to have immunomodulatory properties, apart from the already known antioxidant properties, and is a possible future treatment.[61]
- Use of drugs to suppress myelin-reactive effector memory T cells by blocking voltage-gated Kv1.3 channels in these cells.[62][63][64][65][66]
- Hydralazine Due to its ability to damage myelin nerve sheaths, acrolein may be a factor in the development of multiple sclerosis. The antihypertensive drug hydralazine, a known scavenger of acrolein, was found to reduce myelin damage and significantly improve behavioral outcomes in a mouse model of multiple sclerosis (experimental autoimmune encephalomyelitis).[67]
- Helminthic therapy: A study showed a negative association between multiple sclerosis and infection with intestinal parasites, such as hookworm indicating that parasites may protect against multiple sclerosis.[68][69] Helminth therapy involves ingesting helminth eggs by the names of Trichuris suis, which are non parasitic worms. This is done in hopes that the body will redirect the immune response away from attacking the myelin, which produce lesions, and target the helminths. The study by Dr Fleming shows this is affective in reducing the extent of lesions seen through MRI’s taken before and after the study.[70]
- BCG vaccine: The common, live, attenuated vaccine against tuberculosis, has substantially reduced recurrence of symptoms in multiple sclerosis patients.[71] The frequency of new enhancing lesions as detected by Gd-enhanced MRI was reduced by more than half in 12 patients, comparing the six-month run-in phase to the six-month post BCG phase of the experiment. Persistence at subsequent MR scan was reduced from 18 to 1 lesion, and evolution to black holes was reduced from 28 to 6 lesions.[72] The conventional explanation of such protection is that parasites (including bacteria) modulate the sensitivity of the immune system. BCG appears safe as a treatment for multiple sclerosis.[71][73]
- Low dose naltrexone is also known as LDN. Naltrexone, a pure opiate antagonist, licensed by the FDA for the treatment of alcohol and opioid addictions, is currently being studied at a lower dosage for MS patients. A small, short-duration clinical trial[74] with MS patients was recently conducted at the University of California, San Francisco. In October 2007 data was presented at the European Congress of MS in Prague regarding safety findings of a pilot study of low dose naltrexone therapy in multiple sclerosis by neurological researchers in Milan, Italy.[75] However, no compelling efficacy results for LDN in MS therapy have been published. LDN is currently available to MS patients in the USA by off-label prescription.
- Minocycline: the antibiotic minocycline has shown an effect on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in MS patients over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment relapse rate in patients in the study prior to treatment, no relapses occurred between months 6 and 24. The only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline. Clinical and MRI outcomes in this study were supported by systemic immunological changes and call for further investigation of minocycline in MS.[76][77][78]
- Pixantrone: pixantrone (BBR2778) is an analogue of mitoxantrone devoid of toxic effects on cardiac tissue. It is as potent as mitoxantrone in animal models of MS; however results of human trials had not been published in 2007.[79]
- Plasmapheresis. Pattern II MS lesions have been reported to respond to plasmapheresis,[80] which points to something pathogenic into the blood serum, and the percentaje reported of pattern II is very close to the 47% reported in Kir4.1 MS cases,[81] turning Kir4.1 patients into candidates for plasma exchange.
- Prolactin:In 2007 it was published that the hormone prolactin can ease the effects of demyelination in animal models of MS.[82] This effect of prolactin may be the reason why pregnancy tends to reduce the effects of multiple sclerosis in women.[83]
- Statins: a family of cholesterol-lowering drugs, the statins, have shown anti-inflammatory effects in animal models of MS.[84] However, there is no evidence that statins are beneficial in the treatment of human MS patients, and concerns exist that, if ever shown to be effective, the high doses needed would prevent long-term use due to the potential for liver damage and muscle-wasting disease. One of them, Atorvastatin, has been tried in combination with several approved treatments, though with little success. Other, Simvastatin (Zocor) has shown good results in progressive variants[85]
- Testosterone has been studied for its potential benefits in men with Multiple Sclerosis, but the results are preliminary.[86]
- Vitamin D: a 2004 study found that women who took vitamin D supplements were 40% less likely to develop MS than women who did not take supplements. However, this study does not provide enough data to conclude that vitamin D has a beneficial influence on ongoing MS. Furthermore, it could not distinguish between a beneficial effect of vitamin D and that of multivitamin supplements including vitamin E and various B vitamins, which may also exert a protective effect.[87] A new study in the same sense was published in 2013[88]
- Omega-3 fatty acid: A study found that Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis[89]
Combined therapies
Several combinations of drugs have been tested. Some of them are couples of approved drugs. Other tests try one approved drug with one experimental substance. Finally, at some point there could appear some trials testing couples of non-approved drugs.
As of 2016, there are 10 active principles approved which are: Two interferons (interferon beta-1a and interferon beta-1b), glatiramer acetate, mitoxantrone, fingolimod, teriflunomide,[1] dimethyl fumarate[2] and finally three monoclonal antibodies (natalizumab, alemtuzumab[3] and since May 2016 daclizumab[4][5])
Combination of approved drugs
- Mitoxantrone & Copaxone: A recent study in the United Kingdom revealed interesting results when using a combination of mitoxantrone and copaxone. In an open-label study of 27 patients with RRMS, the results suggested a rapid and sustained suppression of relapses. A three-year controlled study of 60 patients is now being launched at 10 centres across the UK.[90] In another clinical trial, glatiramer acetate (Copaxone) has been combined with Mitoxantrone in such a way that every course of Mitoxantrone is followed by GA treatment. It has yielded promising results twice, in a consistent way.[91][92]
- Tysabri & Copaxone This combination has been found to be safe and well tolerated after six months.[93]
- Mitoxantrone & beta-interferon: This combination has worked in some cases but not in others[94]
- Avonex & Copaxone: Currently in phase III, with good results published[95]
- Interferon beta 1a & Tysabri: Dangerous but effective.[96] Linked with PML, but is remarkable that Natalizumab alone is also linked with it.
- Natalizumab and Fingolimod. No formal research has been done, but some problems have been reported.[97]
- Interferon beta 1a & Glatimer acetate: No additional benefits found[98]
- Alemtuzumab & Copaxone: A combination trial of Alemtuzumab with glatiramer acetate (Copaxone) is being considered, and is expected to work synergistically.[99]
- Laquinimod & Fampridine, with good results, subject to patent where applicable[100]
Approved and experimental drugs combined
- Copaxone & Minocycline. Good results[101]
- Avonex & Atorvastatin: Avonex (beta-1a) has also been combined with Atorvastatin in a clinical trial showing that is safe in its conditions,[102] even though high-dose statins are expected to produce liver problems and muscle-wasting disease over the long-term.[103] Other clinical trials have found problems combining IFN beta with Atorvastatin[104]
- Betaseron & Atorvastatin: Betaseron (beta-1b) has also been combined with Atorvastatin with good safety results but poor performance. The combined treatment did not have any beneficial effects on RRMS compared to IFNB-1b monotherapy.[105]
- Cyclophosphamide & Beta-interferon has been tried on IFNbeta-unresponsive patients with success, but it is still under study.[106]
- Avonex & Inosine: Avonex (interferon beta-1a) was combined with Inosine. Available data suggests that this combination is safe and well tolerated, though with no improvements respect interferon beta alone.[107][108] Recently the lack of additional benefits respect Avonex have been confirmed, and it has been reported that 2gr/day should be considered as the maximum safe dosage.[109]
- Avonex & Lipoic Acid: Lipoic Acid is another common antioxidant[110]
Summary table
Summarizing in a table which combinations have been tried:
Interferon beta-1a | Interferon beta-1b (Betaseron) | Glatiramer acetate (Copaxone) | Mitoxantrone | Natalizumab (Tysabri) | Fingolimod (Gilenya) | Teriflunomide (Aubagio) | Dimethyl fumarate BG12 (Tecfidera) | Alemtuzumab (Lemtrada) | |
---|---|---|---|---|---|---|---|---|---|
Interferon beta-1a | — | — | — | — | — | — | — | — | — |
Interferon beta-1b (Betaseron) | NO | — | — | — | — | — | — | — | — |
Glatiramer acetate (Copaxone) | YES[98] | NO | — | — | — | — | — | — | — |
Mitoxantrone | NO | NO | YES[91][92] | — | — | — | — | — | — |
Natalizumab (Tysabri) | YES (linked to PML) | NO | YES[93] | NO | — | — | — | — | — |
Fingolimod (Gilenya) | NO | NO | NO | NO | NO | — | — | — | — |
Teriflunomide (Aubagio) | NO | NO | NO | NO | NO | NO | — | — | — |
Dymetyl fumarate BG12 (Tecfidera) | NO | NO | NO | NO | NO | NO | NO | — | — |
Alemtuzumab (Lemtrada)[111] | NO | NO | NO | NO | NO | NO | NO | NO | — |
Atorvastatin (Lipitor) | YES | YES[105] | NO | NO | NO | NO | NO | NO | NO |
Cyclophosphamide | NO | YES | NO | NO | NO | NO | NO | NO | NO |
Inosine | YES[107][108] | NO | NO | NO | NO | NO | NO | NO | NO |
Biomarkers for the expected response
Beta-interferons are contraindicated in cases of anti-AQP4 or anti-MOG seropositivity. Interferon injections can induce neutralising antibodies against them, turning the medication ineffective. IFN-β 1b is more immunogenic than IFN-β 1a, and the subcutaneous administration has a higher risk than the intramuscular administration[112] Both interferons should induce MxA mRNA, being its absence a negative indicator[113]
For Glatimer Acetate, the biomarkers for response are interleukins. IL-27 is a biomarker for response, and IL-18 and IL-4 are also possible good biomarkers[114][115]
The best predictive biomarker for Mitoxantrone available is the number of relapses in separate areas within the past 24 months before treatment.[116]
Natalizumab can also induce neutralising antibodies 4 to 6 months after treatment initiation. Fetuin-A (alpha-2-HS-glycoprotein) and circulating CD49 expression are emerging biomarkers for the therapeutic efficacy of natalizumab[112]
References
- 1 2 "FDA approves new multiple sclerosis treatment Aubagio" (Press release). US FDA. 12 September 2012. Retrieved 21 January 2013.
- 1 2 "Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis" (Press release). Biogen Idec. 27 March 2013. Retrieved 4 June 2013.
- 1 2 "FDA Approves Lemtrada". Biogen Idec Press Release. 14 November 2013.
- 1 2 FDA BLA Approval letter May 27, 2016
- 1 2 FDA News Release: FDA approves Zinbryta to treat multiple sclerosis May 27, 2016
- ↑ R.E Gonsette, B. Dubois, Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity, Journal of the Neurological Sciences, Volume 223, Issue 1, 15 August 2004, Pages 81-86. doi: http://dx.doi.org/10.1016/j.jns.2004.04.024
- ↑ clinicaltrial.gov CLARITY Study. Retrieved on 25 November 2007.
- ↑ Merck Serono's Phase III multiple sclerosis trial meets endpoint
- ↑ Giovannoni G, et al., NEJM 2010
- ↑ Merck KGaA Submits Application For Cladribine Tablets As Multiple Sclerosis Therapy In Europe
- ↑ Hope for MS pill after cladribine and fingolimod trials, BBC News;Published 20-January-2010
- ↑ http://www.genengnews.com/gen-news-highlights/merck-serono-gives-up-on-getting-drug-candidate-for-multiple-sclerosis-approved/81245334/
- ↑ Press release
- ↑ Hutas G (November 2008). "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies". Current Opinion in Investigational Drugs. 9 (11): 1206–15. PMID 18951300.
- ↑ Anthony Traboulsee et al. Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies, Neurology April 5, 2016 vol. 86 no. 16 Supplement PL02.004
- ↑ Press Release of the company
- ↑ Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R (March 2010). "Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?". Neurology. 74 (13): 1033–40. doi:10.1212/WNL.0b013e3181d7d651. PMID 20200338.
- ↑ Press Release
- ↑ clinicaltrials.gov
- ↑ Zamboni P, Galeotti R, Menegatti E, et al. (April 2009). "Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis". Journal of Neurology, Neurosurgery & Psychiatry. 80 (4): 392–9. doi:10.1136/jnnp.2008.157164. PMC 2647682. PMID 19060024.
- ↑ Opexa shares lose most of value on study data
- ↑ Opexa Therapeutics Announces Completion Of Mid Study Descriptive Analysis On Phase IIb Trial Of Tovaxin
- ↑ Tovaxin phase III announced http://www.opexatherapeutics.com/?page=release§ion=news&article=010511
- ↑ Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
- ↑
- ↑ Press release of the manufacturing company, 2016
- ↑ clinicaltrial.gov CDP323 Phase II Study. Retrieved on 25 November 2007.
- ↑ Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR (2007). "Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER){alpha} and ER{beta} ligand treatment". Proceedings of the National Academy of Sciences. 104 (37): 14813–8. doi:10.1073/pnas.0703783104. PMC 1976208. PMID 17785421.
- ↑ Palaszynski KM, Liu H, Loo KK, Voskuhl RR (April 2004). "Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis". J Neuroimmunol. 149 (1–2): 84–9. doi:10.1016/j.jneuroim.2003.12.015. PMID 15020068.
- ↑ "Treatment of Multiple Sclerosis Using Over the Counter Inosine". ClinicalTrials.gov. March 16, 2006. Retrieved 2006-05-10.
- ↑ Toncev G (October 2006). "Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis". Vojnosanit Pregl. 63 (10): 879–82. doi:10.2298/VSP0610879T. PMID 17121380.
- ↑ Koch M, De Keyser J (2006). "Uric acid in multiple sclerosis". Neurol. Res. 28 (3): 316–9. doi:10.1179/016164106X98215. PMID 16687059.
- ↑ Rentzos M, Nikolaou C, Anagnostouli M, et al. (2006). "Serum uric acid and multiple sclerosis". Clinical neurology and neurosurgery. 108 (6): 527–31. doi:10.1016/j.clineuro.2005.08.004. PMID 16202511.
- ↑ Chen, Peng; David E. Goldberg; Bryan Kolb; Marc Lanser; Larry I. Benowitz (June 25, 2002). "Inosine induces axonal rewiring and improves behavioral outcome after stroke". PNAS. 99 (13): 9031–9036. doi:10.1073/pnas.132076299. PMC 124418. PMID 12084941. Retrieved 2006-05-10.
- ↑ Liu F, You SW, Yao LP, et al. (2006). "Secondary degeneration reduced by inosine after spinal cord injury in rats". Spinal Cord. 44 (7): 421–6. doi:10.1038/sj.sc.3101878. PMID 16317421.
- ↑ McNaughton L, Dalton B, Tarr J (1999). "Inosine supplementation has no effect on aerobic or anaerobic cycling performance". International journal of sport nutrition. 9 (4): 333–44. PMID 10660865.
- ↑ Markowitz CE, Spitsin S, Zimmerman V, et al. (June 2009). "The Treatment of Multiple Sclerosis with Inosine". The Journal of Alternative and Complementary Medicine. 15 (6): 619–25. doi:10.1089/acm.2008.0513. PMC 3189001. PMID 19425822.
- ↑ Markowitz CE, Spitsin S, Zimmerman V, et al. (June 2009). "The treatment of multiple sclerosis with inosine". J Altern Complement Med. 15 (6): 619–25. doi:10.1089/acm.2008.0513. PMC 3189001. PMID 19425822.
- ↑ Stella Célio Junqueira et al. Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor, Molecular Neurobiology, April 2016
- ↑ Burt RK; Loh, Yvonne; Cohen, Bruce; Stefosky, Dusan; Balabanov, Roumen; Katsamakis, George; Oyama, Yu; Russell, Eric J; Stern, Jessica; Muraro, Paolo; Rose, John; Testori, Alessandro; Bucha, Jurate; Jovanovic, Borko; Milanetti, Francesca; Storek, Jan; Voltarelli, Julio C; Burns, William H; et al. (2009). "Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study". Lancet Neurol. 8 (3): 244–53. doi:10.1016/S1474-4422(09)70017-1. PMID 19186105.
- ↑ Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial, 16 August 2016, The Lancet Neurology
- ↑ "McGill/JGH researchers successfully reverse multiple sclerosis in animals New immune-suppressing treatment forces the disease into remission in mice". McGill University. August 11, 2009. Retrieved 2009-08-12.
- ↑ "Multiple Sclerosis Successfully Reversed In Mice: New Immune-suppressing Treatment Forces The Disease Into Remission". Science Daily. August 12, 2009.
- ↑ Moutih Rafei; Jeremy Hsieh; Simone Zehntner; MengYang Li; Kathy Forner; Elena Birman; Marie-Noëlle Boivin; Yoon Kow Young; Claude Perreault; Jacques Galipeau. (August 9, 2009). "A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties". Nature Medicine. Nature Medicine. 15 (9): 1038–45. doi:10.1038/nm.2003. PMID 19668193. Retrieved 2009-08-12.
- ↑ D'haeseleer M, Beelen R, Fierens Y, Cambron M, Vanbinst AM, Verborgh C, Demey J, De Keyser J (Apr 2013). "Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1". Proc Natl Acad Sci U S A. 110 (14): 5654–8. doi:10.1073/pnas.1222560110. PMID 23509249.
- ↑ Significant Advances in Multiple Sclerosis Treatment http://www.pharmacytimes.com/publications/specialty-pt/2011/February-2011/SPT-NPP-0211
- ↑ Gladstone DE, Zamkoff KW, Krupp L, et al. (2006). "High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis". Arch. Neurol. 63 (10): 1388–93. doi:10.1001/archneur.63.10.noc60076. PMID 16908728.
- ↑ Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Pia Amato M (2007). "Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety". Journal of the Neurological Sciences. 266 (1–2): 25–30. doi:10.1016/j.jns.2007.08.023. PMID 17870094.
- ↑ Krishnan C, Kaplin AI, Brodsky RA, et al. (June 2008). "Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis". Arch. Neurol. 65 (8): 1044–51. doi:10.1001/archneurol.65.8.noc80042. PMC 2574697. PMID 18541787.
- ↑ Jeremy Chataway, Nadine Schuerer, Ali Alsanousi, Dennis Chan, David MacManus, Kelvin Hunter, Val Anderson, Charles R M Bangham, Shona Clegg, Casper Nielsen, Nick C Fox, David Wilkie, Jennifer M Nicholas, Virginia L Calder, John Greenwood, Chris Frost, Richard Nicholas. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet, March 2014 DOI: 10.1016/S0140-6736(13)62242-4
- ↑ Chataway J; et al. (2014). "Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial". The Lancet. 383 (9936): 2213–2221. doi:10.1016/s0140-6736(13)62242-4.
- ↑ Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis
- ↑ Villar LM et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol. 2014 Aug;76(2):231-40. doi: 10.1002/ana.24190. Epub 2014 Jul 2.
- ↑ Bagos PG, Nikolopoulos G, Ioannidis A (2006). "Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis". Mult Scler. 12 (4): 397–411. doi:10.1191/1352458506ms1291oa. PMID 16900753.
- ↑ Sriram S, Yao SY, Stratton C, Moses H, Narayana PA, Wolinsky JS (2005). "Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS". J. Neurol. Sci. 234 (1–2): 87–91. doi:10.1016/j.jns.2005.03.042. PMID 15935383.
- ↑ Oztaş B, Kiliç S, Dural E, Ispir T (November 2001). "Influence of antioxidants on the blood–brain barrier permeability during epileptic seizures". J Neurosci Res. 66 (4): 674–8. doi:10.1002/jnr.10023. PMID 11746387.
- ↑ "Uric Acid In Multiple Sclerosis". 01/02/2006. Archived from the original on 2005-05-07. Retrieved 2006-05-10. Check date values in:
|date=
(help) - ↑ Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC (December 1, 2000). "The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity". Journal of Immunology. 165 (11): 6511–8. doi:10.4049/jimmunol.165.11.6511. PMID 11086092.
- ↑ Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE (2007). "Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology". Brain Research Reviews. 56 (2): 322–30. doi:10.1016/j.brainresrev.2007.07.005. PMID 17761296.
- ↑ Moccia M; et al. (2015). "Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study". J Neurol. 262: 961–7. doi:10.1007/s00415-015-7666-y. PMID 25673130.
- ↑ Liu Y, Li P, Lu J, et al. (August 2008). "Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis". Journal of Immunology. 181 (3): 1887–97. doi:10.4049/jimmunol.181.3.1887. PMID 18641326.
- ↑ Beeton C, Wulff H, Barbaria J, et al. (November 2001). "Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis". Proceedings of the National Academy of Sciences. 98 (24): 13942–7. doi:10.1073/pnas.241497298. PMC 61146. PMID 11717451.
- ↑ Wulff H, Calabresi PA, Allie R, et al. (June 2003). "The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS". Journal of Clinical Investigation. 111 (11): 1703–13. doi:10.1172/JCI16921. PMC 156104. PMID 12782673.
- ↑ Vennekamp J, Wulff H, Beeton C, et al. (June 2004). "Kv1.3-Blocking 5-Phenylalkoxypsoralens: A New Class of Immunomodulators". Molecular Pharmacology. 65 (6): 1364–74. doi:10.1124/mol.65.6.1364. PMID 15155830.
- ↑ Rus H, Pardo CA, Hu L, et al. (August 2005). "The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain". Proceedings of the National Academy of Sciences. 102 (31): 11094–9. doi:10.1073/pnas.0501770102. PMC 1182417. PMID 16043714.
- ↑ Matheu MP, Beeton C, Garcia A, et al. (October 2008). "Imaging of Effector Memory T Cells during a Delayed-Type Hypersensitivity Reaction and Suppression by Kv1.3 Channel Block". Immunity. 29 (4): 602–14. doi:10.1016/j.immuni.2008.07.015. PMC 2732399. PMID 18835197.
- ↑ Leung, G; Sun W; Zheng L; Brookes S; Tully M; Shi R (2010). "Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune enchephalomyelitis mouse". Neuroscience. 173: 150–155. doi:10.1016/j.neuroscience.2010.11.018. PMC 3034379. PMID 21081153.
- ↑ Correale J, Farez M (2007). "Association between parasite infection and immune responses in multiple sclerosis". Annals of Neurology. 61 (2): 97–108. doi:10.1002/ana.21067. PMID 17230481.
- ↑ Correale J, Farez M, Razzitte G (August 2008). "Helminth infections associated with multiple sclerosis induce regulatory B cells". Annals of Neurology. 64 (2): 187–99. doi:10.1002/ana.21438. PMID 18655096.
- ↑ Fleming, JO; Isaak, A.; Lee, J.; Luzzio, C.; Carrithers, M.; Cook, T.; Field, A.; Boland, J.; Fabry, Z. (3 March 2011). "Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study". Multiple Sclerosis Journal. 0: 1–12. doi:10.1177/1352458511398054.
- 1 2 Ristori, G; Buzzi MG; Sabatini U; Giugni E; Bastianello S; Viselli F; Buttinelli C; Ruggieri S; Colonnese C; Pozzilli C; Salvetti M (Oct 1999). "Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis". Neurology. 53 (7): 1588–1589. doi:10.1212/wnl.53.7.1588. PMID 10534275.
- ↑ Paolillo, A; Buzzi MG; Giugni E; Sabatini U; Bastianello S; Pozzilli C; Salvetti M; Ristori G. (February 2003). "The effect of Bacille Calmette-Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS". J Neurol. 250 (2): 247–248. doi:10.1007/s00415-003-0967-6. PMID 12622098.
- ↑ Rutschmann, OT; McCrory, DC; Matchar, DB; Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines (Dec 2002). "Immunization and MS: a summary of published evidence and recommendations". Neurology. 59 (12): 1837–1843. doi:10.1212/wnl.59.12.1837. PMID 12499473.
- ↑ 2007 clinical trial using LDN
- ↑ Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G (2008). "A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis". Multiple Sclerosis. 14 (8): 1076–83. doi:10.1177/1352458508095828. PMID 18728058.
- ↑ Zabad RK, Metz LM, Todoruk TR, et al. (2007). "The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study". Mult. Scler. 13 (4): 517–26. doi:10.1177/1352458506070319. PMID 17463074."It has been available for over 30 years and, in the United Kingdom alone, more than 6.5 million people have been treated with minocycline for an average of 9 months, mostly for acne." Minocycline is probably the most cost effective, and effective treatment available for MS, but its low cost, means that large pharmaceutical companies will fight to prevent its introduction as an MS treatment.
- ↑ May 2003 Emerging Therapies for MS
- ↑ Tilley BC, Alarcón GS, Heyse SP, et al. (January 1995). "Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group". Annals of Internal Medicine. 122 (2): 81–9. doi:10.1001/archinte.122.1.81. PMID 7993000.
- ↑ Gonsette RE, Dubois B (2004). "Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity". J. Neurol. Sci. 223 (1): 81–6. doi:10.1016/j.jns.2004.04.024. PMID 15261566.
- ↑ Wilner AN, Goodman (March 2000). "Some MS patients have "Dramatic" responses to Plasma Exchange". Neurology Reviews. 8 (3).
- ↑ Srivastava R. et Al, Potassium channel KIR4.1 as an immune target in multiple sclerosis, N Engl J Med. 2012 Jul 12;367(2):115-23. doi: 10.1056/NEJMoa1110740, PMID 22784115
- ↑ Gregg C, Shikar V, Larsen P, et al. (2007). "White matter plasticity and enhanced remyelination in the maternal CNS". J. Neurosci. 27 (8): 1812–23. doi:10.1523/JNEUROSCI.4441-06.2007. PMID 17314279.
- ↑ Vukusic S, Confavreux C (2006). "[Multiple sclerosis and pregnancy]". Rev Neurol. (Paris) (in French). 162 (3): 299–309. PMID 16585885.
- ↑ Weber MS, Prod'homme T, Steinman L, Zamvil SS (2005). "Drug Insight: using statins to treat neuroinflammatory disease". Nature Clinical Practice Neurology. 1 (2): 106–12. doi:10.1038/ncpneuro0047. PMID 16932506.
- ↑ Statin may slow progressive MS
- ↑ Sicotte NL, Giesser BS, Tandon V, et al. (2007). "Testosterone treatment in multiple sclerosis: a pilot study". Arch. Neurol. 64 (5): 683–8. doi:10.1001/archneur.64.5.683. PMID 17502467.
- ↑ Munger KL, Zhang SM, O'Reilly E, et al. (2004). "Vitamin D intake and incidence of multiple sclerosis". Neurology. 62 (1): 60–5. doi:10.1212/01.wnl.0000101723.79681.38. PMID 14718698.
- ↑ Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D., Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis
- ↑ Shinto L, Marracci G, Baldauf-Wagner S, et al. (2009). "Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis,☆☆☆". Prostaglandins, Leukotrienes and Essential Fatty Acids. 80 (2–3): 131–6. doi:10.1016/j.plefa.2008.12.001. PMC 2692605. PMID 19171471.
- ↑ United Kingdom early Mitoxantrone Copaxone trial
- 1 2 Vollmer T, Panitch H, Bar-Or A, et al. (June 2008). "Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis". Mult Scler. 14 (5): 663–70. doi:10.1177/1352458507085759. PMID 18424479.
- 1 2 Arnold DL, Campagnolo D, Panitch H, et al. (October 2008). "Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS". J Neurol. 255 (10): 1473–8. doi:10.1007/s00415-008-0911-x. PMID 18854910.
- 1 2 Goodman AD, Rossman H, Bar-Or A, et al. (March 2009). "GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study". Neurology. 72 (9): 806–12. doi:10.1212/01.wnl.0000343880.13764.69. PMC 2821836. PMID 19255407.
- ↑ Zaffaroni M, Rizzo A, Baldini SM, Ghezzi A, Comi G (September 2008). "Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis". Neurol Sci. 29 (Suppl 2): S230–2. doi:10.1007/s10072-008-0946-x. PMID 18690501.
- ↑ NIH Deepens Investment In Combination Study Of MS Drugs
- ↑ Radue EW, Stuart WH, Calabresi PA, et al. (May 2010). "Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis". J. Neurol. Sci. 292 (1–2): 28–35. doi:10.1016/j.jns.2010.02.012. PMID 20236661.
- ↑ http://ccsvi-ms.ning.com/profiles/blogs/severe-relapses-under-fingolimod-treatment-prescribed-after-natal
- 1 2 Common MS Drugs Taken Together Do Not Reduce Relapse Risk
- ↑ "Sanofi and Genzyme Report New Positive Data from First Phase III Study with MS Drug". 24 October 2011.
- ↑ Treatment of multiple sclerosis with combination of laquinimod and fampridine, US Patent US 20160235735 A1
- ↑ Metz LM, Li D, Traboulsee A, et al. (October 2009). "Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial". Multiple Sclerosis. 15 (10): 1183–94. doi:10.1177/1352458509106779. PMID 19776092.
- ↑ Paul F, Waiczies S, Wuerfel J, et al. (2008). Gwinn K, ed. "Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis". PLoS ONE. 3 (4): e1928. doi:10.1371/journal.pone.0001928. PMC 2276246. PMID 18398457.
- ↑ Patient Management in Multiple Sclerosis: A Canadian Expert Viewpoint, Mark S. Freedman
- ↑ Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT (October 2008). "Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis". Neurology. 71 (18): 1390–5. doi:10.1212/01.wnl.0000319698.40024.1c. PMID 18525027.
- 1 2 Kamm CP et al. Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial, PLoS One. 2014 Jan 30;9(1):e86663. doi: 10.1371/journal.pone.0086663. eCollection 2014., PMID 24497963
- ↑ Perini P, Calabrese M, Rinaldi L, Gallo P (September 2008). "Cyclophosphamide-based combination therapies for autoimmunity". Neurol Sci. 29. Suppl 2 (S2): S233–4. doi:10.1007/s10072-008-0947-9. PMID 18690502.
- 1 2 Patient Management in Multiple Sclerosis: A Canadian Expert Viewpoint, Mark S. Freedman
- 1 2 Gonsette RE, Sindic C, D'hooghe MB, et al. (April 2010). "Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial". Mult. Scler. 16 (4): 455–62. doi:10.1177/1352458509360547. PMID 20200198.
- ↑ Muñoz García D; et al. (Oct 2014). "Associated Inosine to interferon: results of a clinical trial in multiple sclerosis". Acta Neurol Scand. 131: 405–410. doi:10.1111/ane.12333.
- ↑ Valentina Durastanti et al. ALPHA LIPOIC ACID AS ADD-ON THERAPY TO SUBCUTANEOUS INTERFERON Β-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PILOT STUDY, International Journal of Applied Biology and Pharmaceutical Technology Page: 336
- ↑ FDA approves Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis
- 1 2 Piero Del Boccio et al. Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine, Proteomics Clinical Applications, Volume 10, Issue , April 2016, Pages 470–484,
- ↑ Tomas Uher et al. Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients, Neurology April 5, 2016 vol. 86 no. 16 Supplement P3.019
- ↑ John E. Mindur et al. IL-27: a potential biomarker for responders to glatiramer acetate therapy, Journal of Neuroimmunology, July 16, 2016, DOI: http://dx.doi.org/10.1016/j.jneuroim.2016.07.004
- ↑ Valenzuela et al. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis, J. Neuroimg. June 2016, DOI: http://dx.doi.org/10.1016/j.jneuroim.2016.06.005
- ↑ M Debouverie et al. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis, Mult Scler August 2004 vol. 10 no. 4 407-412, doi: http://doi.org/10.1191/1352458504ms1066oa
Wikimedia Commons has media related to Multiple sclerosis. |